Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación
Tesis doctoral (DoctoralThesis)
Study of PD-1/LAG-3 signaling in T cells and development of therapeutic strategies to counteract PD-1/LAG-3 mediated resistance to cancer immunotherapy, Estudio de la señalización de PD-1/LAG-3 en los linfocitos T, y desarrollo de estrategias terapéuticas para contrarrestar la resistencia a la inmunoterapia del cáncer mediada por PD-1/LAG-3
El tutor de la tesis es Ignacio José Encío Martínez, A significant number of cancer patients do not benefit from PD-L1/PD-1 blockade
immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms
of resistance by establishing a highly dysfunctional state in T-cells. However, how LAG-3
mechanistically triggers its downstream inhibitory signalling remains largely unknown.
Likewise, how LAG-3 cooperates with PD-1 to stablish a highly dysfunctional state in T cells in
cancer is also unknown. A better understanding of LAG-3 and PD-1/LAG-3 signaling will
uncover the reasons behind intrinsic resistance to PD-1 blockade, develop novel treatments
and improve current therapies.
This PhD thesis comprises the study of PD-1/LAG-3 signaling in T-cells and the development
of therapeutic strategies to counteract PD-1/LAG-3-mediated resistance to cancer
immunotherapy. The results of this thesis have been organized into three chapters. In chapter
1, PD-1/LAG-3 molecular co-signaling mechanisms were identified in T-cells, uncovering CBLB
ubiquitin ligases as potential targets. The combination of CBL-B inhibitors with anti-PD-
1/anti-LAG-3 immunotherapies overcame PD-1/LAG-3-mediated resistance in models of lung
cancer refractory to immunotherapies. In chapter 2, the consequences of PD-1/LAG-3 cosignaling
over the proteome and phosphoproteome associated to the TCR signalosome were
characterized. MYC was identified as an inhibited upstream regulator of PD-1/LAG-3
proteomes and phosphoproteomes in T-cells. In chapter 3, T-cell lines expressing LAG-3
mutants in its signaling domains were engineered and analyzed by quantitative highthroughput
differential proteomics and phosphoproteomics. The pathways and molecules
regulated by each of LAG-3 domains and their effect on the TCR signalosome both in terms of
protein expression and phosphorylation activity were characterized. These results highlighted
the critical role of KIEELE and EP domains to endow LAG-3 with inhibitory functions.
Overall, the results will help to identify the mechanisms of intrinsic resistance to PD-1 blockade
mediated by LAG-3 co-signaling, and uncover novel therapeutic targets to counteract PD-
1/LAG-3-mediated resistance., Financiada por el Instituto de Salud Carlos III (ISCIII), co-financiada por el Fondo Europeo de Desarrollo Regional (fondos FEDER) y el Fondo Social Europeo 'Contratos PFIS: Contratos Predoctorales de Formación en Investigación en Salud' (FI21/00080) para el desarrollo de esta tesis doctoral; y por el Instituto de Salud Carlos III (ISCIII), co-financiada por El Fondo Europeo de Desarrollo Regional (fondos FEDER) y el Fondo Social Europeo 'Ayudas para la movilidad del personal investigador (Modalidad M-AES)' (MV22/00123) para realizar una estancia doctoral internacional de seis meses en University College London (UCL), optando así a la mención de Doctor Internacional., Programa de Doctorado en Ciencias de la Salud (RD 99/2011), Osasun Zientzietako Doktoretza Programa (ED 99/2011)